8-K: IDEAYA Reports Strong Uveal Melanoma Trial Results

IDEAYA Biosciences announced positive median overall survival data for metastatic uveal melanoma and favorable neoadjuvant data for primary uveal melanoma, exceeding historical benchmarks.

Summary

• Positive median overall survival (OS) of 21.1 months and median progression-free survival (PFS) of 7.0 months were observed in 44 first-line metastatic uveal melanoma (mUM) patients treated with darovasertib and crizotinib in the Phase 1/2 OptimUM-01 trial.
• The confirmed overall response rate (ORR) was 34% (14/41) with a 9.0-month median duration of response, and a disease control rate (DCR) of 90% (37/41) was achieved in efficacy-evaluable mUM patients.
• In the Phase 2 OptimUM-09 trial for neoadjuvant darovasertib in primary uveal melanoma (UM), 83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving 20% tumor shrinkage.
• An eye preservation rate of 57.1% (24/42) was observed in Cohort 1 (enucleation recommended patients) who completed primary local therapy, increasing to 95% (19/20) for those with 20% tumor shrinkage.
• Approximately 70% (26/37) of patients in Cohort 2 (plaque brachytherapy eligible) observed a reduction in predicted radiation dose to critical eye structures, and 64.9% (24/37) had a reduced predicted risk of vision loss at 3-years post-plaque brachytherapy.
• Improved visual acuity scores were demonstrated by 54.7% (29/53) of Cohort 1 patients and 60.5% (23/38) of Cohort 2 patients during neoadjuvant darovasertib therapy.
• Darovasertib received U.S. Food and Drug Administration Breakthrough Therapy Designation in the neoadjuvant setting of primary uveal melanoma for enucleation-eligible patients.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong clinical trial data for darovasertib in both metastatic and primary uveal melanoma, significantly exceeding historical benchmarks for overall survival and demonstrating substantial benefits in tumor shrinkage, eye preservation, and visual acuity. The manageable safety profile and FDA Breakthrough Therapy Designation further enhance the positive outlook, indicating a high potential for regulatory approval and market impact.

Positives

• Median overall survival of 21.1 months in first-line metastatic uveal melanoma significantly exceeds the historical median OS of approximately 12 months.
• Median progression-free survival of 7.0 months in first-line metastatic uveal melanoma.
• Confirmed overall response rate of 34% and disease control rate of 90% in efficacy-evaluable metastatic uveal melanoma patients.
• 85% of metastatic uveal melanoma patients achieved any reduction in target lesions.
• 83% of primary uveal melanoma patients demonstrated ocular tumor shrinkage, with 54% achieving 20% tumor shrinkage.
• High eye preservation rate of 57.1% in enucleation-recommended primary uveal melanoma patients, rising to 95% for those with 20% tumor shrinkage.
• Significant reduction in predicted radiation dose to critical eye structures (70% of patients) and reduced predicted risk of vision loss (64.9% of patients) in primary uveal melanoma.
• Improved visual acuity scores observed in over 50% of primary uveal melanoma patients during neoadjuvant treatment.
• Manageable tolerability profile for both combination therapy in mUM and single-agent therapy in primary UM, with low rates of serious adverse events and treatment discontinuation.
• FDA Breakthrough Therapy Designation granted for darovasertib in the neoadjuvant setting of primary uveal melanoma for enucleation-eligible patients.

Negatives

• Most common treatment-related adverse events (>30%) for darovasertib and crizotinib combination included diarrhea, nausea, edema, vomiting, dermatitis, hypoalbuminemia, and fatigue.
• Grade 3 treatment-related adverse events (5%) for the combination therapy included iron-deficiency anemia and pulmonary embolism.
• Grade 3 or higher treatment-related adverse events occurred in 16.8% (16/95) of patients receiving neoadjuvant darovasertib.

Risks

• The potential therapeutic benefits of therapeutics, such as combination therapies and darovasertib, may not be realized.
• The safety and efficacy profile of darovasertib may not be as favorable as currently indicated.
• Uncertainties inherent in the drug development process, including the early stage of development for some programs.
• Challenges in designing and conducting preclinical and clinical trials.
• Uncertainties in the regulatory approval processes and the timing of regulatory filings.
• Challenges associated with manufacturing or commercialization of drug products.
• The outcome of pricing, coverage, and reimbursement negotiations with third-party payors for products.
• Ability to successfully establish, protect, and defend intellectual property.
• Sufficiency of existing cash to fund operations.
• Breakthrough Therapy, Orphan Drug Designation, or an accelerated approval filing do not necessarily translate into drug approval.

Future Outlook

The company is conducting a registration-enabling Phase 2/3 trial (OptimUM-02) of darovasertib and crizotinib in first-line HLA*A2:01-negative metastatic uveal melanoma, targeting median PFS data by year-end 2025 to Q1 2026 to support a potential U.S. accelerated approval filing. An ongoing Phase 3 trial (OptimUM-10) is evaluating single-agent darovasertib in the neoadjuvant setting of primary uveal melanoma, with 20% tumor shrinkage proposed as the definition of response for this trial.

Management Comments

• No direct quotes from company management were provided in the body of the filing, however, the report was signed by Yujiro Hata, President and Chief Executive Officer, indicating management's endorsement of the reported results.

Industry Context

Metastatic uveal melanoma is a rare and aggressive form of ocular cancer with a historically poor prognosis, typically showing a median overall survival of approximately 12 months in treatment-naive patients. The reported median OS of 21.1 months for the darovasertib and crizotinib combination represents a significant improvement over this historical benchmark, potentially offering a new standard of care. The neoadjuvant use of darovasertib in primary uveal melanoma, demonstrating high rates of tumor shrinkage, eye preservation, and visual acuity improvement, addresses a critical unmet need for therapies that can reduce the necessity for enucleation and preserve vision, which are major concerns for patients with this disease.

Comparison to Industry Standards

• The median overall survival (OS) of 21.1 months for darovasertib and crizotinib in first-line metastatic uveal melanoma (mUM) significantly surpasses the historical median OS of approximately 12 months reported in published meta-analyses for treatment-naive mUM patients.
• The proportion of patients with ECOG Performance Status 1 in the OptimUM-01 study (39%) is approximately two times higher than in an earlier published registrational study in mUM, suggesting the trial included a sicker patient population, making the positive OS data even more compelling.
• The 95% eye preservation rate in primary uveal melanoma patients with 20% tumor shrinkage prior to primary local therapy, following neoadjuvant darovasertib, represents a substantial improvement over traditional enucleation rates for large tumors, offering a significant benefit in organ and vision preservation.

Related Party Transactions

• Pfizer provided IDEAYA Biosciences with a defined quantity of crizotinib at no cost and an additional defined quantity at a lump-sum cost, pursuant to a Clinical Trial Collaboration and Supply Agreement to evaluate darovasertib and crizotinib as a combination therapy in metastatic uveal melanoma.

Stakeholder Impact

• **Shareholders:** Highly positive clinical trial results and regulatory designations are likely to increase investor confidence and potentially drive share price appreciation.
• **Patients:** The reported data offers significant hope for improved outcomes, including extended survival for metastatic uveal melanoma and eye/vision preservation for primary uveal melanoma, addressing critical unmet medical needs.
• **Healthcare Providers:** The promising data suggests a potential new, more effective treatment option for a rare and aggressive cancer, which could change clinical practice guidelines.
• **Pfizer:** The positive results from the collaboration validate their crizotinib contribution and could lead to further strategic partnerships or commercial benefits.
• **Regulatory Bodies (FDA):** The Breakthrough Therapy Designation and plans for accelerated approval filing indicate a streamlined path for review, potentially bringing the therapy to patients faster.

Next Steps

• Presentation of OptimUM-01 data at the 2025 Society for Melanoma Research Congress on October 26, 2025.
• Targeting to report median PFS data from the registration-enabling Phase 2/3 OptimUM-02 trial by year-end 2025 to Q1 2026.
• Potential U.S. accelerated approval filing for darovasertib and crizotinib in first-line HLA*A2:01-negative metastatic uveal melanoma.
• Ongoing Phase 3 trial (OptimUM-10) of single-agent darovasertib in the neoadjuvant setting of primary uveal melanoma, with 20% tumor shrinkage proposed as the definition of response.

Key Dates

Recommendation

The filing presents exceptionally strong clinical data for darovasertib, both as a combination therapy in metastatic uveal melanoma (mUM) and as a monotherapy in neoadjuvant primary uveal melanoma (UM). The median overall survival of 21.1 months in mUM significantly exceeds the historical benchmark of 12 months, indicating a substantial clinical benefit in a highly aggressive cancer. Furthermore, the high rates of tumor shrinkage, eye preservation, and visual acuity improvement in primary UM address critical unmet needs. The manageable safety profile and the FDA Breakthrough Therapy Designation for neoadjuvant UM underscore the drug's potential and a clear path towards accelerated approval. These results position IDEAYA Biosciences favorably for future regulatory success and market penetration, making it a compelling 'strong buy' for investors seeking exposure to innovative oncology therapeutics.

Keywords

Uveal Melanoma, Darovasertib, Crizotinib, Clinical Trial, Oncology, Metastatic Cancer, Eye Cancer, Breakthrough Therapy, FDA, IDEAYA Biosciences